menu
    • menu
    [{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131 Group","sponsor":"CURIUM US LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Radiolabelled Compounds","year":"2025","type":"Acquisition","leadProduct":"Lu-177 PSMA-I&T","moa":"PSMA","graph1":"Oncology","graph2":"Phase III","graph3":"Eczac\u0131ba\u015f\u0131 Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC","highestDevelopmentStatusID":"10","companyTruncated":"Eczac\u0131ba\u015f\u0131 Group \/ CURIUM US LLC"},{"orgOrder":0,"company":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","sponsor":"FutureChem","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"TURKEY","productType":"Other Small Molecule","year":"2022","type":"Partnership","leadProduct":"177-Ludotadipep","moa":"PSMA","graph1":"Oncology","graph2":"Phase I","graph3":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem","highestDevelopmentStatusID":"6","companyTruncated":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products \/ FutureChem"}]

    Find Clinical Drug Pipeline Developments & Deals by Eczacıbaşı Group

    Menu

    Eczacıbaşı Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eczacıbaşı Group

                            Turkey arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eczacıbaşı Group

                            Turkey arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : CURIUM US LLC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Curium Completes Monrol Acquisition To Expand Lutetium-177 Capacity

                            Details : The acquisition enhances Curium’s manufacturing of Lutetium-177 to meet the growing demand for isotope around the world. Curium’s Lu-177 (Lutetium-177 PSMA-I&T) is being evaluated for Prostate Cancer.

                            Product Name : Curium Lu-177

                            Product Type : Radiolabelled Compounds

                            Upfront Cash : Undisclosed

                            March 28, 2025

                            Lead Product(s) : Lutetium-177 PSMA-I&T,Lutetium (177Lu) Zadavotide Guraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : CURIUM US LLC

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eczacıbaşı-Monrol Nuclear Products

                            Turkey arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eczacıbaşı-Monrol Nuclear Products

                            Turkey arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Ludotadipep

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : FutureChem

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Monrol and FutureChem Announced a Clinical Supply Partnership

                            Details : 177Lu-FC705 belongs to the 2nd generation of albumin binders introduced drugs. Its hydrophilicity is higher than that of other compounds, and has low nonspecific binding.

                            Product Name : 177-Lu FC705

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 18, 2022

                            Lead Product(s) : 177-Ludotadipep

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : FutureChem

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth